There’s a phrase circulating in pharmaceutical commerce circles right now that deserves a permanent place in every independent pharmacist’s vocabulary. The unbundling of the apothecary. It describes something that is no longer theoretical. It is already operating at scale, and it is reshaping who owns the relationship with your patients.
The Disruptors Built the Blueprint First
The pharmaceutical industry relied for the better part of a century on a fortress of opacity. Companies like Hims & Hers, Ro, and Thirty Madison engineered a parallel supply chain, replacing the fragmented handoffs of the legacy system with a vertically integrated stack combining asynchronous telemedicine, proprietary pharmacy fulfillment, and aggressive consumer brand marketing. By owning the physician relationship through the professional corporation model and the fulfillment node through compounding facilities, these platforms effectively disintermediated the wholesaler and the PBM for a growing share of chronic conditions.
The telehealth insurgents proved the model worked commercially. The acquisition of Thirty Madison by Remedy Meds signaled that the market was moving toward massive, multi-specialty platforms that could amortize backend costs across diverse patient populations.
Then Pharma Stopped Watching and Started Building
For years, the pharmaceutical industry viewed DTC telehealth as a nuisance. In 2024, Eli Lilly validated the model by launching LillyDirect, a strategic pivot that forced other manufacturers to follow suit.
Leading manufacturers launched direct-to-patient programs that combine transparent cash-pay pricing with telehealth and home delivery: LillyDirect from Eli Lilly, PfizerForAll, NovoCare Pharmacy from Novo Nordisk, AstraZeneca Direct, AmgenNow, Bristol Myers Squibb’s Eliquis 360 Support, and Novartis’s Cosentyx pilot. This isn’t just a logistics tweak. It’s a shift in who owns the relationship with the patient.
As offerings mature, a spectrum is emerging. Full-service platforms such as LillyDirect and PfizerForAll integrate prescribing, payment, and care navigation, while targeted programs such as AstraZeneca Direct focus on affordability and access.
PfizerForAll helps patients schedule telehealth services, fill prescriptions, and access savings programs for the company’s migraine, COVID-19, and flu medicines, in addition to scheduling vaccinations for pneumococcal pneumonia and RSV. Patients can use existing insurance and pharmacy programs but also benefit from new direct services from partners including UpScriptHealth, Instacart, and Alto Pharmacy.
The pace of adoption across the industry confirms this is now standard pharma strategy, not an isolated experiment. Eliquis and Xarelto, blockbuster blood thinners with patents expiring between 2026 and 2028, illustrate where this is heading next. While handling anticoagulants requires more rigorous monitoring than hair loss pills, the integration of connected devices like smartwatches detecting AFib makes this feasible. Capturing the aging demographic on a heart health subscription would represent the final maturation of DTC into primary care.
Pharma Is Saying the Quiet Part Out Loud
The most important detail in this entire trend is not the platforms themselves. It is how openly pharma leadership describes the ambition.
By the time one industry survey ran in August and September 2025, 73% of pharma leaders said they were running or planning to launch a direct-to-patient program within the next year.
By offering a cash-pay price for Zepbound vials that bypasses insurance, Lilly is effectively telling consumers: your insurance is the problem, not our drug price. The flat cash price removes the sticker shock of high-deductible plans where a patient might be asked to pay over $1,000 at the counter. And by selling directly, Lilly captures patient data, adherence rates, side effect reporting, demographic shifts, that was previously hoarded by PBMs and pharmacies.
That data capture detail matters as much as the pricing strategy. The manufacturer that owns the direct relationship doesn’t just sell more units. It builds a longitudinal data asset about its own patients that no pharmacy, no PBM, and no payer can access. That is durable competitive value, and it compounds over time.
The Strategic Logic, Stated Plainly
The reasoning behind this industry-wide pivot is explicit, and pharmacists should understand it precisely because it explains why this trend is not slowing down.
If manufacturers do not build direct bridges to patients, tech-enabled insurgents will build them instead, and those insurgents will charge a toll for standing between the manufacturer and the patient. Pharma is not doing this because it wants to operate pharmacies. It is doing this because whoever owns the last mile of the patient relationship captures the most durable value in the entire healthcare system.
For a century, that role belonged to the local pharmacist by default, almost by accident of geography. Patients went to the pharmacy nearest their home or their doctor’s office because that was the only practical option. That default is now being actively, deliberately challenged by companies with far more capital and far more patience than any single independent pharmacy can match.
Most major pharmaceutical companies have now launched a direct platform, spanning LillyDirect, PfizerForAll, NovoCare, AstraZeneca Direct, AmgenNow, and a growing number of specialty programs across cardiometabolic, respiratory, neurology, and autoimmune conditions. While each company has its own strategy, the underlying forces are shared: patients want convenience, transparency, and immediate access; pharma wants predictable economics and relief from PBM distortion; policymakers want lower list prices and alternatives to traditional distribution models.
Even the Disruptors Know They Need You
Here is the part of this story that should genuinely change how every community pharmacist thinks about the threat, because buried inside the most aggressive direct-to-patient platform in the industry is an admission that should reframe the entire conversation.
“LillyDirect aims to address the fragmentation and friction patients face across their healthcare journey,” said Jennifer Mazur, Senior Vice President and General Manager, U.S. LillyDirect and Consumer Hub, Eli Lilly. “Our goal isn’t only to improve access to Lilly therapies, but to help patients connect with independent care providers and trusted information.”
Read that quote again. The manufacturer with the most sophisticated direct-to-patient platform in the industry explicitly frames its own product as a bridge to independent providers, not a replacement for them. And the platform’s own structural decisions confirm this is not just marketing language.
LillyDirect offers access to independent telehealth providers that could complement a patient’s current primary care team or be an alternative, and an independent search tool that allows a patient to find healthcare professionals near them if they prefer in-person care.
HealthTap became the first independent telehealth primary care provider option available on LillyDirect, offering patients living with type 1 and type 2 diabetes access to longitudinal primary care. “Our virtual-first model makes it easier for patients to build long-term relationships with doctors who can oversee their full care journey, not just issue one-time prescriptions,” said HealthTap co-founder Dr. Geoffrey Rutledge.
knownwell, an in-person and virtual weight-inclusive primary care and metabolic health company, also joined as a care provider option on LillyDirect. “Options for personalized, comprehensive, and high-quality clinical care are an even greater unmet need,” said CEO Brooke Boyarsky Pratt, noting that the platform creates a healthcare home for patients with overweight and obesity rather than simply dispensing medication.
Lilly went so far as to expand this independent-provider model into a condition where the home delivery component doesn’t even apply. When LillyDirect expanded to facilitate access to Alzheimer’s disease care, the platform deliberately did not include mail order pharmacy options. Instead, it focused entirely on education and pathways to connect patients to independent provider options, including a doctor locator tool and an independent telehealth provider specializing in neurodegenerative care. “We hope to help patients identify and access additional independent specialty care capacity, which can coordinate with a patient’s existing care team,” said David Hyman, MD, Lilly’s chief medical officer.
Translation: even the company that built the most advanced direct-to-patient infrastructure in the industry knows it cannot manufacture the clinical credibility, the trust, and the longitudinal relationship that an independent provider builds with a patient over time. That credibility is exactly what an ongoing pharmacist relationship provides, and no telehealth platform, however well-funded, can replicate a pharmacist who knows a patient’s full medication history, family situation, and health trajectory across years.
Why a Price War Is a Losing Strategy
The instinct for many independent pharmacists watching this trend will be to compete on price. That instinct needs to be retired immediately.
You cannot win a cash-pricing war against a manufacturer selling its own drug. NovoCare, AmgenNow, and AstraZeneca Direct offer flat cash pricing because the manufacturer is selling at a price point it controls entirely, with no wholesaler markup, no PBM spread, and no independent pharmacy margin built into the chain. Flat cash pricing at these platforms highlights what drugs cost without rebates, pressuring the secrecy of PBM-negotiated pricing structures that independent pharmacy reimbursement has historically depended on. No community pharmacy can match that economics on the same product.
The pharmacies that try to compete on price against a manufacturer’s own direct channel are fighting a battle they cannot win, with capital they don’t have, against an opponent with no urgency to ever stop investing.
The Moat That Infinite Manufacturer Capital Cannot Buy
The defensible position is the one Lilly’s own leadership identified by building independent provider connections directly into their platform. Longitudinal, trusted, in-person clinical relationship is the asset that no amount of capital can manufacture quickly, because it is built one patient interaction at a time, over years, through consistent, accurate, personally attentive care.
This is not an abstract claim. It is the explicit structural admission embedded in LillyDirect’s own architecture, in NovoCare’s referral pathways, and in every direct-to-patient platform that has chosen to partner with independent providers rather than attempt to replace them entirely.
The pitch every independent pharmacist should be making to patients right now is not “we’re cheaper than the manufacturer’s direct channel.” That pitch loses every time. The pitch is “we’re the ones who actually know you.” That is the moat. It is the only one that survives contact with infinite manufacturer capital, because it cannot be purchased, only built.
Your Strategic Move This Week
Stop framing LillyDirect, NovoCare, PfizerForAll, and the rest as competitors to out-price. Start framing them as evidence of exactly what the manufacturers themselves believe is missing from their own model.
Audit your patient relationships for depth, not volume. Identify your top 50 patients by clinical complexity, polypharmacy, chronic disease burden, or longitudinal relationship length. For each one, ask whether your pharmacy is delivering the kind of comprehensive, personally attentive, longitudinal care that a manufacturer’s telehealth platform structurally cannot replicate. If the honest answer is no that gap is your highest-priority business risk and your highest-leverage opportunity simultaneously.
Build the explicit pitch into every patient conversation. Not a slogan, an actual conversation: “I’ve been your pharmacist for years. I know your full medication history, I know your other conditions, and I know what’s worked and what hasn’t for you specifically. That’s something a website can’t offer you, no matter how convenient the shipping is.” Say it directly. The manufacturers building these platforms already believe this is true. Make sure your patients hear it from you before they hear the alternative pitch from someone else.
The unbundling of the apothecary is real, it is well-funded, and it is not slowing down. The pharmacists who understand exactly what these platforms cannot replicate, and who build their entire practice around that exact gap, have a five-year head start on everyone still trying to compete on price.
Sources: DrugPatentWatch (The Unbundling of the Apothecary: How Vertically Integrated Telehealth Is Dismantling the Pharmaceutical Value Chain, January 19, 2026), Rock Health (Pharma’s Direct-to-Patient Era: Building Beyond Table Stakes, December 9, 2025), Galen Growth (Pharma’s Direct-to-Patient Pivot: LillyDirect, PfizerForAll and NovoCare Models, November 25, 2025), IntuitionLabs (Direct-to-Patient Pharma Platforms: DTC Disruption Models), Thinkers360 / S3 Connected Health (Pharma’s Direct-to-Patient Era: What’s Next; Setting a New Benchmark for Pharma’s Direct-to-Patient Shift), Fierce Pharma (2026 Forecast: Pharma Clicks With Patients as Direct Sales Model Shifts Marketing Strategies, December 19, 2025), AJMC (Pfizer Enters Direct-to-Consumer Market With Telehealth, Prescription Services and More), Pharmaphorum (DTC Pharma Is America’s Newest Care Pathway, TrumpRx Has Exposed the Vacuum Surrounding It, December 2, 2025), Stock Titan / PR Newswire (LillyDirect Platform Expands to Facilitate Access to Alzheimer’s Disease Care; Lilly Launches End-to-End Digital Healthcare Experience Through LillyDirect, January 2024), BusinessWire (HealthTap Expands Access to Primary Care-Driven Diabetes Treatment Through LillyDirect, October 2025; knownwell Connects With LillyDirect to Increase Access to Independent Comprehensive Metabolic Care, April 2025), Healthline (Zepbound Soon Available Through Home Delivery Service)